Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 17INDUSTRY 8NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Burkitt Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Biphenotypic, Acute 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Methotrexate 29Cytarabine 28Vincristine 26Cyclophosphamide 25Mercaptopurine 20Dexamethasone 20pegaspargase 18Prednisone 17Doxorubicin 17Daunorubicin 16Asparaginase 15merphos 14Calcium Dobesilate 14Thioguanine 13Leucovorin 13Radiotherapy 11Hydrocortisone 10azathiopurine 9Filgrastim 9Etoposide 9Granulocyte Colony-Stimulating Factor 8dexamethasone acetate 7dexamethasone 21-phosphate 7auricularum 7Specimen Handling 7prednylidene 6deltacortene 6Whole-Body Irradiation 6Methylprednisolone 6fludarabine phosphate 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Inotuzumab Ozogamicin × Clear all
NCT01925131 2023-05-03

S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia

SWOG Cancer Research Network

Phase 1 Completed
50 enrolled 14 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡